TheranosticTrials.org

Clinical Trial · NCT02755675

uPAR-PET for Prognostication in Patients With Non-small Cell Lung Cancer, Malignant Pleural Mesothelioma and Large Cell Neuroendocrine Carcinoma of the Lung

Overview

uPAR PET/CT as a prognostic marker in non-small cell lung cancer.

Sponsor

National University Hospital, Singapore

Phase

Phase 2

Contacts

Andreas Kjaer, MD,DMSc,PhD (CONTACT)

akjaer@sund.ku.dk

+4535454011

Malene M Clausen, MD, PhD (CONTACT)

malene.martini.clausen@regionh.dk

+4522524536

ClinicalTrials.gov

NCT02755675

Drug / Compound

FDG

Isotope(s):
Target(s):
  • Glucose Transport
Ligand Class: Small Molecules

Eligibility

Inclusion

  • Histologically verified LCNEC (Study III)
  • The participants must be capable of understanding and giving full informed written consentStudy III
  • Study I
  • The participants must be capable of understanding and giving full informed written consent
  • Operable disease
  • Histologically verified MPM (Study II)
  • Histologically verified NSCLC (Study I)
  • The participants must be capable of understanding and giving full informed written consentStudy II
  • Stage IV disease

Exclusion

  • Study I, II, III
  • Treatment with neoadjuvant chemotherapy
  • Pregnancy
  • Lactation/breast feeding
  • Allergy to 68Ga-NOTA-AE105
  • Weight above 140 kg